Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.

Fu-Shun YenJames Cheng-Chung WeiLu-Ting ChiuChih-Cheng HsuMing-Chih HouChii-Min Hwa

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

Compared with nonuser, TZD users demonstrated significantly higher MACE risks. Therefore, the risks of cardiovascular complications should be considered when prescribing TZDs to patients with T2DM and cirrhosis.

Keyphrases

cardiovascular events
coronary artery disease
human health
cardiovascular disease
primary care
risk assessment
risk factors
type diabetes
adverse drug
insulin resistance